Viz.ai has partnered with Avicenna.AI in an effort to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease.
It is hoped that the collaboration will pave the way for faster clinical decision making and care for patients suffering from these two life threatening conditions.
Avicenna.AI’s FDA-approved algorithms for PE and Type A and Type B aortic dissection (AD), leveraged on the Viz intelligent care coordination platform, aim to empower multidisciplinary care teams to easily coordinate patient care by sending notifications paired with dynamic imaging and detailed patient information to each provider’s desktop or mobile device as soon as a PE or an aortic dissection is detected.
As part of Viz.ai’s commercial aortic module offering, access to imaging and workflows supporting the coordination of care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis and transection will be available in addition to the AD algorithm. Similarly, the PE algorithm will be available on Viz.ai’s commercial PE module.
Richard Saxon, interventional radiologist at Tri-City Medical Center (Oceanside, USA), said: “The addition of AI powered workflows should decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening PE and aortic disease, as it has in the treatment of ischaemic stroke. It will help to facilitate faster and easier treatment decisions across health systems, and this should improve outcomes for patients.”
Cyril Di Grandi, chief executive officer of Avicenna.AI, said: “We are proud to become a trusted partner of Viz.ai, who is committed to giving access to high-standard healthcare systems worldwide. Thanks to our AI-based solutions, we hope to facilitate an optimal medical response within a short time frame and improve patient care. We look forward to bringing the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond.”
PE is a potentially deadly form of venous thromboembolic disease, a common cause of cardiovascular death, and is associated with multiple inherited and acquired risk factors affecting hundreds of thousands of people every year globally. PE occurs when a blood clot gets lodged in an artery in the lung, blocking blood flow to part of the lung. Similar to PE, aortic disease is potentially deadly and can require urgent surgical intervention to prevent death.
Chris Mansi, Viz.ai CEO and co-founder, added: “We’re delighted to partner with Avicenna to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz platform, where any patient with life threatening diseases can benefit from AI powered triage, fast mobile communication and synchronized care coordination.
“This partnership will bring the advantages of artificial intelligence to more patients and help hospitals achieve better clinical outcomes.”
